Clinical Trial Update: Double-blinded, 6 Months Study With Bydureon® or Placebo in Adolescents With Obesity to Explore Changes in BMI [Phase 2]

View source ↗

Summary

Phase 2 double-blind trial in adolescents with obesity comparing Bydureon to placebo to assess changes in BMI is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Bydureon (exenatide)

Snippet

Sponsor: Uppsala University | Conditions: Obesity | Phase 2 | Status: COMPLETED